Estrogen

Vaginal estrogen, vaginal dehydroepiandrosterone, oral ospemifene and vaginal moisturizers result in short-term improvements in vaginal atrophy symptoms, known as genitourinary syndrome of menopause, but more long-term data are needed.

At 12 weeks, vaginal hyaluronic acid and vaginal estrogen were associated with similar benefits in the treatment of atrophic vaginitis, known as genitourinary syndrome of menopause, according to results of a pilot trial.

CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting.

An oral herbal supplement with glucosinolates, phytosterols and citrus flavonoids was associated with some improved menopausal symptoms short term compared with estrogen plus progestogen therapy, researchers reported in Menopause.

This is the first installment of the Healio | Women’s Health & OB/GYN Nourish to Flourish column, edited by Susan Weiner, MS, RDN, CDN, CDCES, FADCES. In future installments, Weiner and Healio will speak with experts to discuss the impact of food and nutrients on women’s health.

In the first years of use, women prescribed conjugated estrogens/bazedoxifene vs. estrogen/progestin for menopausal symptoms may have higher rates of endometrial cancer and endometrial hyperplasia but lower breast cancer rates.

Application of adjunctive perioperative vaginal estrogen failed to reduce prolapse recurrence after native tissue transvaginal prolapse repair compared with placebo, according to study results published in JAMA.

Among combined hormonal contraceptive users, those with a history of migraine without aura had a significantly increased risk for ischemic stroke compared with those without a history of migraine, data show.

Women in China may be at greater risk for stroke events following menopause, according to a study published in Neurology.